CD19 and acute lymphoblastic leukemia: Blinatumomab, a BiTE therapy that targets CD19 expressed on ALL blasts as well as CD3 expressed on immune T-cells, is a promising therapy in patients with Ph-negative ALL, regardless of risk group.